LENZ Therapeutics, Inc. — Director's Dealing 2021

Jun 25, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2021-06-24

Reporting Person: Stultz Katherine V (CHIEF OPERATING OFFICER)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	207894	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (8126)		Direct
Stock Option (right to buy)	$0.30	2031-01-12	Common Stock (99753)		Direct
Stock Option (right to buy)	$6.11	2031-03-16	Common Stock (209846)		Direct

Footnotes

F1: These shares of the Issuer's Series B Preferred Stock will automatically convert on a 2.432-for-one basis into the number of shares of the Issuer's common stock shown in Column 3 immediately upon closing of the Issuer's initial public offering without payment of additional consideration. The Series B Preferred Stock has no expiration date.

F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after August 31, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.

F3: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.